GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

A large cohort study finds GLP-1 receptor agonists linked to lower graft loss and mortality in kidney transplant recipients ...

How GLP-1 analogs are reshaping diabetes care and obesity treatment and unlocking potential in cardiovascular, inflammatory, ...

GLP-1 agonists, also known as incretin mimetics ... these medications have been shown to reduce cardiovascular risks and improve kidney function," said Haynes-Ferere. Anecdotally, individuals ...

The 5-year unadjusted cumulative incidence of death-censored graft loss from a cohort matched on survival time before GLP-1 RA initiation was 6.0% for GLP-1 RA users and 10.7% for nonusers.

Kidney transplant recipients with type 2 diabetes prescribed GLP-1 receptor agonists had 31% lower mortality vs. nonusers. GLP-1 receptor agonist use was associated with 49% lower incidence of ...

A major new study finds that certain diabetes medications, including GLP-1 and SGLT2 inhibitors, may be linked to a reduced ...

UK: A systematic review and meta-analysis of randomized trials have highlighted the significant benefits of long-acting ...

In patients with heart failure with preserved ejection fraction and obesity, tirzepatide improved clinical outcomes compared ...

The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

It belongs to the class of drugs called glucagon-like peptide-1 receptor agonists (GLP-1 agonists ... It is also approved to reduce the risk of worsening kidney function in adults with type ...